Clinical Trial

A Study of the Use of Acellular Dermal Matrix for Breast Reconstruction

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The researchers are doing this study to look at the number of complications that occur immediately after prepectoral breast reconstruction when Acellular Dermal Matrix (ADM) is used compared to when ADM is not used. These complications include infections, the need for Tissue Expander (TE) or implant removal, and other conditions that lead to additional surgery.
Protocol Amendment History 8 amendments
This ClinicalTrials.gov record has been amended 8 times since 2022-03-30; most recent amendment 2026-02-13.
Status change: Recruiting → Active, Not Recruiting 2025-02-12
Trial Details
NCT Number NCT05316324
Lead Sponsor Memorial Sloan Kettering Cancer Center
Collaborators: The Plastic Surgery Foundation
Conditions Breast Cancer
Enrollment 353 participants
Start Date 2022-03-23
Primary Completion 2027-03 (estimated)
Study Completion 2027-03 (estimated)
Updated on ClinicalTrials.gov 2026-02-17